

Draft Proposal for Comments and Inclusion in The Indian Pharmacopoeia

Aciclovir Eye Ointment

Published on: 07 February, 2024

Last date for comments: 22 March, 2024

This draft proposal contains monograph text for inclusion in the Indian Pharmacopoeia (IP). The content of this draft document is not final, and the text may be subject to revisions before publication in the IP. This draft does not necessarily represent the decisions or the stated policy of the IP or Indian Pharmacopoeia Commission (IPC).

Manufacturers, regulatory authorities, health authorities, researchers, and other stakeholders are invited to provide their feedback and comments on this draft proposal. Manufacturers are also invited to submit samples of their products to the IPC to ensure that the proposed monograph adequately controls the quality of the product(s) they manufacture. Comments and samples received after the last date will not be considered by the IPC before finalizing the monograph.

Please send any comments you may have on this draft document to lab.ipc@gov.in, with a copy to Dr. Gaurav Pratap Singh (email: gpsingh.ipc@gov.in) before the last date for comments.

Document History and Schedule for the Adoption Process

Description	Details
Document version	1.0
First draft published on IPC website for public comments	February 7, 2024
Last date for comments	March 22, 2024
Monograph revisions proposed for inclusion in	IP 2026
Tentative effective date of monograph revisions	July, 2026
Draft revision published on IPC website for public comments	--
Further follow-up action as required.	

Aciclovir Eye Ointment. Page 1377

Change to: Aciclovir Eye Ointment

Acyclovir Eye Ointment

Aciclovir Eye Ointment is a sterile preparation containing Aciclovir in a suitable base.

Aciclovir Eye Ointment contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of aciclovir, $C_8H_{11}N_5O_3$.

Usual strengths. 3 per cent w/w; 5 per cent w/w.

Identification

A. Disperse a quantity of the eye ointment containing 10 mg of Aciclovir in 60 ml of *hexane*. Extract with three 30 ml quantities of *0.1M sodium hydroxide*, add sufficient *0.1M sodium hydroxide* to produce 100 ml and filter. To 15 ml of this solution, add 5 ml of *2 M hydrochloric acid* and dilute to 100 ml with *water*. When examined the solution in the range 230 nm to 350 nm (2.4.7), shows an absorption maximum at about 255 nm and a broad shoulder at about 274 nm.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Solvent mixture. 20 volumes of *dimethyl sulphoxide* and 80 volumes of *water*.

Test solution. Disperse a quantity of eye ointment containing 25 mg of Aciclovir in 10 ml of *dimethyl sulphoxide* and dilute to 25.0 ml with the solvent mixture, filter.

Reference solution (a). A 0.001 per cent w/v solution of *aciclovir IPRS* in *dimethyl sulphoxide*. Dilute 2.0 ml of the solution to 10.0 ml with the solvent mixture.

Reference solution (b). Dissolve 5 mg of *aciclovir for system suitability A IPRS* in 1 ml of *dimethyl sulphoxide* and dilute to 5 ml with *water*.

Reference solution (c). Dissolve the content of a vial of *aciclovir for impurity C identification IPRS* in 200 μ l of *dimethyl sulphoxide* and dilute to 1 ml with *water*.

Reference solution (d). Dissolve the content of a vial of *acyclovir for impurity G identification IPRS* in 1 ml of reference solution (b) (*NOTE- prepare the solution immediately before use*).

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 μ m) (Such as Supelcosil LC-18-DB),
- mobile phase: A. a mixture of 99 volumes of a buffer solution prepared by dissolving 3.48 g of *dipotassium hydrogen orthophosphate* in 1000 ml of *water*, adjusted to pH 3.1 with *orthophosphoric acid* and 1 volume of *acetonitrile*,
B. a mixture of 50 volumes of a buffer solution prepared by dissolving 3.48 g of *dipotassium hydrogen orthophosphate* in 1000 ml of *water*, adjusted to pH 2.5 with *orthophosphoric acid* and 50 volumes of *acetonitrile*,
- a gradient programme using the conditions given below,
- flow rate: 1 ml per minute,
- spectrophotometer set at 254 nm,
- injection volume: 10 μ l.

Time (in min.)	Mobile phase A (per cent v/v)	Mobile phase B (per cent v/v)
0	100	0
5	100	0
27	80	20

40	80	20
40.1	100	0
50	100	0

Name	Relative retention time	Correction factor
Aciclovir impurity B ¹	0.4	---
Aciclovir impurity C ²	0.9	2.2
Aciclovir (Retention time: about 13 minutes)	1.0	---
Aciclovir impurity K ³	2.5	---
Aciclovir impurity G ⁴	2.6	---

¹2-amino-1,7-dihydro-6H-purin-6-one (guanine),

²2-amino-7-[(2-hydroxyethoxy)methyl]-1,7-dihydro-6H-purin- e-one,

³2,2'-(methylenediazanediyl)bis[9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one],

⁴2-[(2-acetamido-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl acetate.

Inject reference solution (c) and (d) to identify the peak due to impurity C and peaks due to aciclovir impurity B, G and K respectively.

Inject reference solution (c) and (b). The test is not valid unless the resolution between the peaks due to aciclovir impurity C and aciclovir is not less than 1.5 in the chromatogram obtained with reference solution (c) and between the peaks due to aciclovir impurity K and aciclovir impurity G is not less than 1.5 in the chromatogram obtained with reference solution (d).

Inject reference solution (a) and the test solution. In the chromatogram obtained with the test solution the area of any peak corresponding to aciclovir impurity B is not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent), the area of any other secondary peak is not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent), and the sum of the areas of all the secondary peaks is not more than 10 times the area of the principal peak in the chromatogram obtained with reference solution (a) (2.0 per cent). Ignore any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent).

Other tests. Comply with the tests stated under Eye Ointment.

Assay. Determine by liquid chromatography (2.4.14).

Solvent mixture. 20 volumes of *dimethyl sulphoxide* and 80 volumes of *water*.

Test solution. Disperse a quantity of eye ointment containing 25 mg of Aciclovir in 10 ml of *dimethyl sulphoxide* and dilute to 25.0 ml with the solvent mixture. Dilute 1.0 ml of the solution to 10.0 ml with the solvent mixture.

Reference solution (a). Dissolve 25 mg of *aciclovir IPRS* in 10 ml of *dimethyl sulphoxide* and dilute to 25.0 ml with the solvent mixture. Dilute 1.0 ml of the solution to 10.0 ml with the solvent mixture.

Reference solution (b). Dissolve the content of a vial of *aciclovir for impurity C identification IPRS* in 200 µl of *dimethyl sulphoxide* and dilute to 1 ml with *water* (NOTE- Prepare the solution immediately before use).

Use chromatographic system as described under Related substances.

Inject reference solution (b). The test is not valid unless the resolution between the peaks due to aciclovir impurity C and aciclovir is not less than 1.5.

Inject reference solution (a) and the test solution.

Calculate the content of C₈H₁₁N₅O₃ in the eye ointment.